{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:15:12Z","timestamp":1770142512672,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serum hepatitis B virus (HBV) pregenomic RNA (pgRNA) predicts antiviral response in adults with chronic hepatitis B (CHB); however, its prognostic performance against conventional biomarkers in children remains underexplored. This study aimed to characterize the kinetics of pgRNA and hepatitis B surface antigen (HBsAg) and evaluate their predictive value for treatment outcomes in children with CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-five hepatitis B e antigen (HBeAg)-positive children with CHB who received \u2265 96 weeks of nucleos(t)ide analogue (NA) therapy were included. Serum viral biomarkers were measured at baseline, weeks 12, 48, and 96. Treatment outcomes were HBeAg seroconversion and HBsAg loss (Defined as HBsAg &amp;lt;100 IU\/mL or seroclearance).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients initiating treatment before age 7 years had a significantly higher cumulative incidence of HBeAg seroconversion (73.5% vs. 48.4%) and HBsAg loss (50.0% vs. 9.7%) compared to older children (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Week 12 HBV pgRNA decline was an independent predictor of HBeAg seroconversion (area under the curve [AUC] = 0.793, 95% confidence interval [CI]: 0.686\u20130.900), outperforming HBV DNA and HBsAg kinetics. For predicting HBsAg loss, the week 12 HBsAg decline was an independent predictor (AUC\u00a0=\u00a00.762, 95% CI: 0.632\u20130.893), and its integration with patient age further improved predictive accuracy (AUC\u00a0=\u00a00.879, 95% CI: 0.796\u20130.962).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early pgRNA kinetics more accurately predict HBeAg seroconversion, whereas HBsAg dynamics forecast HBsAg loss more effectively, particularly when combined with patient age. This complementary monitoring strategy provides a clinically applicable tool for optimizing personalized management in children with CHB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1746541","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T06:30:52Z","timestamp":1770100252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaorong","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunan","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/hep.32479","article-title":"Circulating HBV RNA: From biology to clinical applications","volume":"76","author":"Deng","year":"2022","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference Faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1282922","article-title":"Efficacy of pegylated interferon \u03b1-2b plus entecavir therapy and predictors of treatment success in children with chronic hepatitis B","volume":"14","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.gastro.2012.06.009","article-title":"Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B","volume":"143","author":"Kennedy","year":"2012","journal-title":"Gastroenterology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00535-025-02211-5","article-title":"Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B","volume":"60","author":"Kosaka","year":"2025","journal-title":"J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e29670","DOI":"10.1002\/jmv.29670","article-title":"Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B","volume":"96","author":"Lai","year":"2024","journal-title":"J. Med. Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14050495","article-title":"Long-term HBsAg titer kinetics with entecavir\/tenofovir: implications for predicting functional cure and low levels","volume":"14","author":"Lee","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.14218\/JCTH.2023.00014","article-title":"Functional cure of chronic hepatitis B with antiviral treatment in children having high-level viremia and normal or mildly elevated serum aminotransferase","volume":"11","author":"Li","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/apt.16149","article-title":"Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)","volume":"53","author":"Lim","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3350\/cmh.2024.0724","article-title":"Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters","volume":"31","author":"Mak","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1002\/hep.31616","article-title":"HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy","volume":"73","author":"Mak","year":"2021","journal-title":"Hepatology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3350\/cmh.2022.0448","article-title":"The role of different viral biomarkers on the management of chronic hepatitis B","volume":"29","author":"Mak","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3350\/cmh.2022.0172","article-title":"Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B","volume":"29","author":"Mak","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e184243","DOI":"10.1172\/JCI184243","article-title":"Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment","volume":"135","author":"Taddese","year":"2025","journal-title":"J. Clin. Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.14218\/JCTH.2025.00064","article-title":"Emerging serum biomarkers for chronic hepatitis B: focus on serum HBV RNA and HBcrAg","volume":"13","author":"Tian","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van B\u00f6mmel","year":"2015","journal-title":"Hepatology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12072-023-10597-8","article-title":"Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high","volume":"18","author":"Wang","year":"2024","journal-title":"Hepatol. Int."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients","author":"Wang","year":"2017","journal-title":"J. Hepatol."},{"key":"B25","unstructured":"Global hepatitis report 2024: action for access in low- and middle-incomes countries\n          \n          \n          \n          2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.17235\/reed.2025.11226\/2025","article-title":"Serum HBV RNA as a predictive biomarker for HBeAg seroconversion during entecavir and tenofovir disoproxil fumarate therapy in chronic hepatitis B patients","volume":"117","author":"Wu","year":"2025","journal-title":"Rev. Esp Enferm Dig."},{"key":"B27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jinf.2021.08.044","article-title":"On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B","volume":"83","author":"Wu","year":"2021","journal-title":"J. Infect."},{"key":"B28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/apt.17667","article-title":"Age at treatment initiation predicts response in children with chronic hepatitis B","volume":"58","author":"Wu","year":"2023","journal-title":"Aliment Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/apt.16538","article-title":"Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment","volume":"54","author":"Xia","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antiviral Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.14218\/JCTH.2023.00320","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s12072-023-10631-9","article-title":"Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol. Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jhep.2019.06.009","article-title":"Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B","volume":"71","author":"Zhu","year":"2019","journal-title":"J. Hepatol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1746541\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T06:30:54Z","timestamp":1770100254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1746541\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":33,"alternative-id":["10.3389\/fcimb.2026.1746541"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1746541","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1746541"}}